Efficacy and safety of Stitivastatin 80 mg/day in hypercholesterolemic patients

American Journal of Cardiology

Volumn 82, Issue 3, 1998, Pages 311-316

  Stein, Evan A ^b   Davidson, Michael H ^b   Dobs, Adrian S ^b   Schrott, Helmut ^b   Duiovne, Carlos A ^b   Bays, Harold ^b   Weiss, Stuart R ^b   Melino, Michael R ^b   Stepanavage, Michael E ^b   Mitchel, Yale B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOPATHY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SAFETY; SIMVASTATIN; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 0031928765     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9149(98)00421-4     Document Type: Article

References (28)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Data on file. Merck Research Laboratories, Rahway, NJ, USA.
3. Davidson MH, Stein EA, Dujovne CA, Hunninghake DB, Weiss SR, Knopp RH, Illingworth DR, Mitchel YB, Melino MR, Zupkis RV, Dobrinska MR, Amin RD, Tobert JA. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997;79:38-42.
4. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-49.
5. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-682.
6. Pedersen TR, Berg K, Cook TJ, Færgeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyôrälä K, Thorgeirsson G, Tobert JA, Wedel H, Wilhelmsen L. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996;156:2085-2092.
7. Krauss RM, Deckelbaum RJ, Ernst N, Fisher E, Howard BV, Knopp RH, Kotchen T, Lichtenstein AH, McGill HC, Pearson TA, Prewitt TE, Stone NJ, Horn LV, Weinberg R. Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association. Circulation 1996;94:1795-1800.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
9. Myers G, Cooper G, Winn C, Smith S. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med 1989;9:105-135.
10. Steiner P, Freidel J, Bremner W, Stein E. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the lipid clinics' methodology. J Clin Chem 1981;19:850.
11. Warnick G, Albers J. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res 1978;19:65-76.
12. Stein E, Kreisberg R, Miller V, Mantell G, Washington L, Shapiro DR. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I. Arch Intern Med 1990;150:341-345.
13. Santer S, Santen R, Kulin H, Demers L. A model for validation of radioimmunoassay kit reagents: measurement of follitropin and lutropin in blood and urine. Clin Chem 1981;27:1892-1895.
14. Tdx System Operator's Manual, Abbott Diagnostics, Abbot Park, IL, 1993.
15. Newton WT, McGuigan JE, Jaffe BM. Radioimmunoassay of peptides lacking tyrosine. J Lab Clin Med 1970;75:886-892.
16. Stubbs RJ, Schwartz MS, Gerson RJ, Thornton TJ, Bayne WE. Comparison of plasma profiles of lovastatin (mevinolin), simvastatin (epistatin), and pravastatin (eptastatin) in the dog. Drug Invest 1990;2 (suppl. 2):18-28.
17. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen, Kristoffersen B, Tobert JA, Musliner TA, Cook, TJ. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-1460.
18. Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 1992;41:487-498.
19. Watts GF, Cummings MH, Umpleby M, Quiney JR, Naoumova R, Thompson GR, Sonksen PH. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Eur J Clin Invest 1995;25:559-567.
20. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81:66B-69B.
21. Stein EA, Davidson MH, Dujovne CA, Hunninghake DB, Goldberg RB, Illingworth DR, Kropp RH, Milles VT, Frost P, Isacsohn JL, Mitchel YB, Melino MR. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardovasc Pharmacol Ther 1996;1:107-116.
22. Bruckert E, De Gennes JL, Malbecq W, Baigts F. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Clin Cardiol 1995;18:621-629.
23. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease. A reappraisal. Drug Saf 1996;14:11-24.
24. Wang RW, Kari PH, Lu AY, Thomas PE, Guengerich FP, Vyas KP. Bio transformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991;290:355-361.
25. Yang B-B, Siedlik PH, Smithers JA, Sedman AJ, Stern RH. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates; erythromycin and ethinyl estradiol. Pharm Res 1996;13:S437.
26. Neuvonen PJ, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharm Ther 1996;60:54-61.
27. Domestic product circular: Zocor® (simvastatin), 1997.
28. Domestic product circular: Lipitor® tablets (atorvastatin calcium), 1997.